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Introduction
Treatments of severe rheumatic conditions in children
are increasingly based on biologics. The most common
adverse events on all kind of biologics are mild infections
in ENT, pulmonary and urinary systems. The number of
cases of varicella-zoster-virus (VZV) manifestations while
being on biologics is constantly growing. No consensus
exists about what to do when facing this situation yet.
Objectives
The aim of this work is to describe the French experience
of VZV infection/reactivation management in children
affected with chronic inflammatory rheumatisms and
treated with available biologics in a real life setting.
Methods
French pediatric rheumatologists were asked through
the web site of the Société Francophone des rhumatismes
et maladies inflammatoires de l’enfant -SOFREMIP- by
phone and/or e-mail to report their cases of VZV manifes-
tations on biologics using a standardized and anonymized
e-CRF.
Results
21 cases of VZV infection/reactivation were reported in
children less than 18 yrs, followed for rheumatic condi-
tions treated with biotherapies. 19 had JIAs of which 9 had
systemic JIAs, 1 had SLE, 1 had polyarthritis with immune
deficiency. Biologics-associated treatments were NSAIDs
in 5 cases, steroids in 9 cases, DMARDs in 14 (MTX
in 12, MMF and HCQ in 1, AZA in 1). Biologics were
anti-TNFs in 13 children (9 ETN, 4 ADA), anti-IL1 in
6 (4 CNK, 2 ANK), 1 had TCZ, and 1 RTX. A long delay
was observed between the initiation of biologics and the
VZV manifestations in the majority of patients, whatever
the biologic. None of our cases was vaccinated against
VZV. 12 children had varicella (7 with concurrent anti-
TNF treatment, 4 with anti-IL1, 1 with RTX) and
9 patients had herpes zoster (6 with anti-TNFs, 2 with
anti-IL1, 1 with TCZ). 2 patients had a complicated clini-
cal picture of VZV infection/reactivation: 1 had an
ophthalmic zoster and 1 had a systemic dissemination of
VZV with severe hepatic involvement and pancytopenia.
NSAIDs were stopped 4 times out of 5 continuous treat-
ment, steroids were stopped in 1/9 patients, DMARDs
were interrupted in 8/14, and biologics in 15/21 cases.
16/21 patients received a specific anti-herpetic drug
despite a common non-complicated outcome, whereas
5 children were not treated in the same situation (3 on
anti-TNFs, 2 on anti-IL1). All patients had favorable
outcomes.
Conclusion
This study shows an overrepresentation of systemic JIAs
among patients infected by or reactivating the VZV.
This group of patients may be more immunosuppressed
than others. In spite of the great heterogeneity of VZV
management in France in children treated with biologics,
the outcome was invariably good. This suggests 2 impor-
tant points (i) VZV control may not need any of the cyto-
kines/pathways targeted by the biologics we use, (ii) VZV
management on biologics should be rationalized.
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